leukemia
Conditions
Interventions
Gold Standard:Clinical outcome and laboratory index
Index test:unique 
identifier 
labeled 
super 
sequencing
Sponsors
Children's Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: (1) the diagnosis of acute leukemia was confirmed and the typing test was improved. Before the admission, the patients had not received any anti-tumor treatment including hormone. (2) at the time of diagnosis, LAIP, leukemia fusion gene and Wes sequencing were found. (3) be able to receive treatment and bone marrow examination evaluation according to the standard treatment plan. (4) the age of the unit is 0-18 years old (including boundary value); (5) agree with the examination plan and follow-up plan specified in the clinical trial plan, and actively cooperate; (6) the guardian of the patient agrees to participate in the clinical trial and sign ICF, indicating that he understands the purpose and procedure of the clinical trial and is willing to participate in the study. Patients = 8 years old signed ICF with the consent of their guardian, indicating that they understood the purpose and procedure of this clinical trial and were willing to participate in the study.
Exclusion criteria
Exclusion criteria: (1) secondary acute leukemia, such as chronic myeloid leukemia, myelodysplastic syndrome related leukemia, primary immunodeficiency disease-related leukemia; (2) previous history of tumor diseases; (3) other conditions that are not suitable to participate in the study or affect the analysis of the results of the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRD level;Event free survival;SPE, SEN, ACC, AUC of ROC; | — |
Countries
China
Contacts
Public ContactJianwen Xiao
Children's Hospital of Chongqing Medical University
Outcome results
None listed